The In Plan Roth 401(k) Conversion That Saves a $400,000 Earner $58,000 in Future RMD Taxes
Picture a 55-year-old earning $400,000 with $1.5 million in a traditional 401(k).
RMD - ResMed Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$281.29
DETAILS
HIGH:
$345.00
LOW:
$225.00
MEDIAN:
$275.00
CONSENSUS:
$281.29
UPSIDE:
35.20%
Stock News
Is the Options Market Predicting a Spike in ResMed Stock?
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Resmed Announces Participation in the 46th Annual William Blair Growth Stock Conference
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed's webcast presentation will begin at approximately 4:40 p.m. (Central Time).
Silver Economy Investing: Why the Healthcare Giants Are in Focus
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Resmed and ŌURA Partner to Expand Access to Sleep Health Education and Care
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world's leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better and improve their overall health. Sleep is increasingly recognized as a key pillar of long-term health, yet it remains widely underprioritized.1 Early signs of poor sleep are often dismissed, creating a gap between what people experience and when they seek support or clinical care.
A Look at ResMed Inc (RMD) After 3.9% Decline -- GF Value $270.01 vs Price $198.76
On May 11, 2026, ResMed Inc (RMD) shares fell 3.9% to a current price of $198.76. This decline comes amid broader market pressures, with the stock now trading c
10 Dividend Growth Stocks: May 2025
Dividend growth stocks have a streak of at least 5 consecutive years of dividend increases. I rank a selection of dividend growth stocks and present the top 10 stocks for consideration. To rank stocks, I do a quality assessment and sort candidates by quality scores. My new quality scoring system rates dividend stocks on a 10-point scale across 9 weighted factors. Each factor blends qualitative signals and quantitative metrics.
Here's Why ResMed (RMD) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
Resmed beats Q3 earnings and revenue estimates with strong margin gains, yet shares slip post earnings despite growth across key segments.
ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
Revenue: $1.43 billion, an 11% increase year-over-year, 8% in constant currency.Gross Margin: 62.8%, increased by 290 basis points year-over-year.Operating Mar
ResMed (RMD) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for ResMed (RMD) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
ResMed (RMD) Surpasses Q3 Earnings and Revenue Estimates
ResMed (RMD) came out with quarterly earnings of $2.86 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.37 per share a year ago.
ResMed beats quarterly profit estimates, names new CFO
Medical device maker ResMed beat third‑quarter profit estimates on Thursday, driven by strong demand for its medical devices, while appointing Aaron Bloomer as its new chief financial officer.
Resmed Chief Financial Officer Brett Sandercock to Retire; Aaron Bloomer Appointed as Successor
SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced that Brett Sandercock, Chief Financial Officer, plans to retire effective May 4, 2026. After conducting a comprehensive search, Aaron Bloomer has been appointed as his successor.
Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
Revenue increased by 11% to $1.4 billion; up 8% on a constant currency basis GAAP gross margin up 290 bps to 62.2%; non-GAAP gross margin up 290 bps to 62.8% GAAP income from operations increased 17%; non-GAAP income from operations up 18% GAAP diluted earnings per share of $2.74; non-GAAP diluted earnings per share of $2.86 Operating cash flow of $554 million; $262 million returned to shareholders through share repurchases and dividends Note: A webcast of Resmed's conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com SAN DIEGO, April 30, 2026 (GLOBE NEWSWIRE) -- Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended March 31, 2026.
Wall Street's Insights Into Key Metrics Ahead of ResMed (RMD) Q3 Earnings
Besides Wall Street's top-and-bottom-line estimates for ResMed (RMD), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Arizona State Retirement System Trims Stock Position in ResMed Inc. $RMD
Arizona State Retirement System cut its holdings in shares of ResMed Inc. (NYSE: RMD) by 7.6% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 40,076 shares of the medical equipment provider's stock after selling 3,297 shares during the quarter. Arizona
ResMed (RMD) Reports Next Week: Wall Street Expects Earnings Growth
ResMed (RMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Resmed's Q3 Earnings on Deck: What's in Store for the Stock?
RMD gears up for fiscal Q3 earnings with steady estimates, rising demand in sleep devices and AI-driven digital health tools poised to shape results.
Why ResMed (RMD) is Poised to Beat Earnings Estimates Again
ResMed (RMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Price Targets
ResMed price target lowered to $225 from $254 at Baird
$225.00
(was $203.87)
Robert W. Baird
ResMed price target lowered to $290 from $302 at KeyBanc
$290.00
(was $219.85)
KeyBanc
ResMed price target lowered to $255 from $300 at Evercore ISI
$255.00
(was $228.33)
Anthony Petrone
·
Evercore ISI
ResMed price target raised to $314 from $311 at RBC Capital
$314.00
(was $254.08)
Craig Wong-Pan
·
RBC Capital
ResMed price target raised to $265 from $260 at Stifel
$265.00
(was $257.61)
Stifel Nicolaus
ResMed price target raised to $302 from $299 at KeyBanc
$302.00
(was $257.61)
Brett Fishbin
·
KeyBanc
ResMed price target raised to $281 from $275 at Baird
$281.00
(was $257.61)
Robert W. Baird
ResMed price target raised to $275 from $270 at Piper Sandler
$275.00
(was $257.61)
Piper Sandler
ResMed (RMD) PT Lowered to $260 at Stifel
$260.00
(was $245.94)
Jonathan Block
·
Stifel Nicolaus
ResMed downgraded to Neutral from Outperform at Baird
$275.00
(was $253.07)
Robert W. Baird
ResMed (RMD) PT Raised to $345 at UBS
$345.00
(was $251.38)
Marcus Curley
·
UBS
ResMed price target lowered to $300 from $320 at Baird
$300.00
(was $246.88)
Robert W. Baird
ResMed price target raised to $299 from $298 at KeyBanc
$299.00
(was $244.12)
Brett Fishbin
·
KeyBanc
ResMed price target raised to $305 from $304 at Morgan Stanley
$305.00
(was $252.26)
David Bailey
·
Morgan Stanley
ResMed price target raised to $304 from $298 at Morgan Stanley
$304.00
(was $271.41)
Morgan Stanley
ResMed initiated with an Equal Weight at Wells Fargo
$280.00
(was $272.00)
Wells Fargo
Morgan Stanley sees 'modest' earnings impact to ResMed from Apnimed
$286.00
(was $248.14)
David Bailey
·
Morgan Stanley
ResMed price target raised to $274 from $269 at KeyBanc
$274.00
(was $232.65)
Brett Fishbin
·
KeyBanc
ResMed price target lowered to $265 from $280 at Mizuho
$265.00
(was $211.49)
Anthony Petrone
·
Mizuho Securities
ResMed price target lowered to $240 from $250 at Stifel
$240.00
(was $223.83)
Stifel Nicolaus